[DOC][DOC] Literature Review of International Biosimilar Medicines: Update December 2017–February 2018
M Ward, SR Lange, K Staff, P MPharm - health.gov.au
Apart from rights as permitted by the Copyright Act 1968 (Cth) or allowed by this copyright
notice, all other rights are reserved, including (but not limited to) all commercial …
notice, all other rights are reserved, including (but not limited to) all commercial …
[DOC][DOC] Literature review of international biosimilar medicines: update June–September 2016
M Ward, SR Lange, K Staff, P MPharm - Canberra (AU): Department of … - health.gov.au
Apart from rights as permitted by the Copyright Act 1968 (Cth) or allowed by this copyright
notice, all other rights are reserved, including (but not limited to) all commercial …
notice, all other rights are reserved, including (but not limited to) all commercial …
[PDF][PDF] Biosimilars: Fundamentals and authorization as per US perspective
SS Manikiran, LP Nori - researchgate.net
Biosimilars are biological products that are the replicas of their innovator
biopharmaceuticals. At the moment, biological products account for 10-15% of the total …
biopharmaceuticals. At the moment, biological products account for 10-15% of the total …
Biosimilars: state of clinical and regulatory science
AV Klein, J Wang, BG Feagan… - Journal of Pharmacy & …, 2017 - journals.library.ualberta.ca
Abstract On May 12, 2017, various issues and challenges associated with biologics were
discussed during a session of the annual joint conference of Canadian Society for …
discussed during a session of the annual joint conference of Canadian Society for …
Biologics, biosimilars, intended copies and the era of competitive medicine
C Ghia, D Shah, G Rambhad, A Mubashir… - Apollo medicine, 2015 - Elsevier
Biologics have helped treatment of diseases including cancers, rheumatoid arthritis, etc. in
entirely new ways. Because they are expensive, there is a demand for generic versions …
entirely new ways. Because they are expensive, there is a demand for generic versions …
Biosimilar drugs: concerns and opportunities
AA Genazzani, G Biggio, AP Caputi, M Del Tacca… - BioDrugs, 2007 - Springer
Patents for biologic agents first marketed in the 1980s are now beginning to expire, opening
the door for 'nonproprietary'versions of these agents to enter the market. However, there are …
the door for 'nonproprietary'versions of these agents to enter the market. However, there are …
Biosimilar medicines: Increasing access to modern essential medicines while supporting sustainability of healthcare systems
A van den Hoven - Journal of Generic Medicines, 2017 - journals.sagepub.com
Biologic medicines have revolutionised the management of many serious diseases over the
last three decades. However, the potential of biologic medicines has not been fully realised …
last three decades. However, the potential of biologic medicines has not been fully realised …
[HTML][HTML] Biosimilars and the real world
N Ledón, A Lage - MEDICC review, 2017 - SciELO Public Health
Biotechnology has changed the pharmacopeia. It is expected that in the next five years, 50%
of biological products will originate from biotechnology. Yet, treatments based on effective …
of biological products will originate from biotechnology. Yet, treatments based on effective …
The rise of the biosimilar
M McCamish, G Woollett - Expert Review of Clinical Pharmacology, 2012 - Taylor & Francis
Full article: The rise of the biosimilar Skip to Main Content Taylor and Francis Online homepage
Taylor and Francis Online homepage Log in | Register Cart 1.Home 2.All Journals 3.Expert …
Taylor and Francis Online homepage Log in | Register Cart 1.Home 2.All Journals 3.Expert …
[PDF][PDF] A Brave New World of Biosimilars
C Denton - education.healthtrustpg.com
A Brave New World of Biosimilars Page 1 A Brave New World of Biosimilars Christie Denton,
PharmD, PGY2 Drug Information Resident Rutgers, The State University of New Jersey …
PharmD, PGY2 Drug Information Resident Rutgers, The State University of New Jersey …